2015-04-21T11:42:55-05:00 2014-06-30 941254756 HOOD & STRONG LLP 100 FIRST STREET 14TH FLOOR SAN FRANCISCO CA 94105 990 2013-07-01 030485196 MYELIN REPAIR FOUNDATION MYEL 4088712410 18809 COX AVENUE NO 190 SARATOGA CA 95070 DENISE ST ONGE CFO 4088712410 2015-04-08 1 MAGA E KISRIEV P01008919 4157810793 2013 2016-02-25 16:41:14Z SCOTT JOHNSON 18809 COX AVENUE NO 190 SARATOGA CA 95070 3519067 0 X WWW.MYELINREPAIR.ORG X 2002 CA ACCELERATING THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MS. 6 5 20 20 0 0 4428671 3463318 0 0 -12114 -3087 -37000 21665 4379557 3481896 1749400 1648750 0 0 1891625 2633342 0 0 1465429 1857400 2004071 5498425 6286163 -1118868 -2804267 7317764 4343784 575013 405300 6742751 3938484 X THE MYELIN REPAIR FOUNDATION GRANTS FUNDS FOR RESEARCH TO DEVELOP RATIONAL DRUG TARGETS TO SLOW, STOP, AND ULTIMATELY REPAIR DAMAGE TO MYELIN CAUSED BY MULTIPLE SCLEROSIS. THE FOUNDATION HAS A DEFINED PROCESS FOR COLLABORATION AMONG SCIENTISTS AND WITH BUSINESSES THAT SUBSTANTIALLY SHORTENS THE TIME TO DISCOVERY OF THE MECHANISMS FOR MYELIN REPAIR AS WELL AS THE TIME TO COMMERCIALIZE THESE MECHANISMS IN THE FORM OF TREATMENTS FOR MS PATIENTS. 0 0 4354113 1648750 21500 THESE AMOUNTS INCLUDE ALL RESEARCH AND DEVELOPMENT PROGRAM SERVICES INCLUDING DISCOVERY BIOLOGY, TRANSLATIONAL MEDICINE AND CLINICAL. SEE LARGEST PROGRAM SERVICE ACCOMPLISHMENTS BELOW. DISCOVERY BIOLOGY: MRF MAINTAINED AND EXPANDED ITS DISCOVERY BIOLOGY EFFORTS BY MANAGING AND FUNDING A WORLDWIDE CONSORTIUM OF OVER 50 RESEARCHERS. THIS YEAR, IN COLLABORATION WITH THE HERTIE FOUNDATION, TWO GERMANY-BASED INVESTIGATORS WERE IDENTIFIED THAT HAVE SINCE BEEN ADDED TO MRF'S DISCOVERY BIOLOGY CONSORTIUM. TRANSLATIONAL MEDICINE: MRF SCREENED OVER 700 COMPOUNDS FROM THE NIH KNOWN-DRUGS LIBRARY IN OLIGODENDROCYTE DIFFERENTIATION ASSAY, OUT OF WHICH 27 KNOWN DRUGS THAT PROMOTE OLIGODENDROCYTE DIFFERENTIATION WERE IDENTIFIED AND INDEPENDENTLY CONFIRMED. IN ADDITION, MRF INCREASED THE CAPACITY AND RELIABILITY OF OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION ASSAYS AS WELL AS ADDED AND OPTIMIZED A HIGH-CAPACITY OLIGODENDROCYTE PROTECTION ASSAY. AS A RESULT, MRF NOW HAS A SUITE OF 4 ASSAYS AVAILABLE WHICH FACILITATED THE ADDITION OF 6 NEW PARTNERSHIPS/COLLABORATIONS. CLINICAL: A COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) WAS FINALIZED WITH THE NATIONAL INSTITUTES OF HEALTH (NIH) TO ESTABLISH A LEGAL FRAMEWORK FOR COLLABORATION BETWEEN THE NIH AND MRF TO CONDUCT PHASE 1 AND PHASE 2 OF A HUMAN CLINICAL TRIAL CLINICAL OF MRF-008. 4354113 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 39 0 1 20 1 0 0 0 0 0 1 1 0 0 0 0 0 X 6 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X DENISE ST ONGE 4088712410 18809 COX AVENUE 190 SARATOGA CA 95070 SCOTT JOHNSON CEO 40.00 X X 289500 0 39809 JIM GIDWITZ BOARD MEMBER 1.00 X 0 0 0 SHARON WIENBAR BOARD MEMBER 1.00 X 0 0 0 CASEY MCGLYNN BOARD MEMBER 1.00 X 0 0 0 ANDY CATES BOARD MEMBER 1.00 X 0 0 0 BOBBY MEHTA BOARD MEMBER 1.00 X 0 0 0 JAY TUNG CRO 40.00 X 214654 0 38889 DENISE ST ONGE CFO 6.00 X 61900 0 0 TASSIE COLLINS DIRECTOR 40.00 X 187910 0 16252 JASON DUGAS ASSOCIATE DIRECTOR 40.00 X 128396 0 17843 VIRGINIA SAIFER CDO 40.00 X 169140 0 31287 1051500 0 144080 8 0 1 0 WILSON SONSINI GOODRICH AND ROSATI 650 PAGE MILL ROAD PALO ALTO CA 94304 PATENT AND LEGAL SERVICES 382314 MIKE PLEISS AND ASSOCIATES LLC 848 STELLA COURT SUNNYVALE CA 94087 RESEARCH CONSULTING 114000 2 3463318 53836 3463318 1256 1256 32828 32754 4417 74 -4417 -4343 -4343 OTHER INCOME 900099 21665 21500 165 21665 3481896 21500 0 -2922 1588750 1588750 60000 60000 1268180 733460 47508 487212 991513 299944 183595 507974 215566 46282 56538 112746 158083 66580 20327 71176 61550 61550 1904 1904 23435 23435 347069 272457 13027 61585 31453 31453 39191 16717 5181 17293 89572 42335 4387 42850 333461 229545 37974 65942 101389 45088 3850 52451 12207 11258 949 27910 19575 2778 5557 11090 4530 2187 4373 PATENT EXPENSES 434352 434352 DRUG TARGET VALIDATION 176080 176080 ANNUAL RESEARCH MEETING 159341 159341 TRANSLATIONAL MEDICINE 146498 146498 7569 1321 2380 3868 6286163 4354113 466621 1465429 4988116 1618879 2204410 2540712 26521 63200 118485 51902 63807 66583 34910 54410 7317764 4343784 433946 405300 141067 575013 405300 X 4190341 1397772 2552410 2540712 6742751 3938484 7317764 4343784 -2804267 0 X 0 1 X 1 0 X 12165768 1528919 1761904 4428671 3463318 23348580 12165768 1528919 1761904 4428671 3463318 23348580 13258375 10090205 10978 26870 7382 4420 1256 50906 76500 23960 67204 19500 21665 208829 23608315 0.42740 0.42350 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 23402 11701 11701 53546 7891 45655 41537 32310 9227 66583 X 3642560 160664 160664 3481896 0 3481896 6446827 160664 160664 6286163 0 6286163 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME AND CALIFORNIA FRANCHISE TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND SECTION 23701(D) OF THE CALIFORNIA REVENUE AND TAXATION CODE, RESPECTIVELY. ADDITIONALLY, THE FOUNDATION HAS BEEN DETERMINED BY THE INTERNAL REVENUE SERVICE NOT TO BE A PRIVATE FOUNDATION WITHIN THE MEANING OF SECTION 509(A) OF THE INTERNAL REVENUE CODE. THE FOUNDATION FOLLOWS FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS CODIFICATION TOPIC 740 INCOME TAXES TO ACCOUNT FOR UNCERTAIN TAX POSITIONS. MANAGEMENT HAS CONCLUDED THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS GUIDANCE. THE FOUNDATION IS GENERALLY NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY FEDERAL TAX AUTHORITIES FOR TAX YEARS ENDING JUNE 30, 2010 AND BEFORE AND BY CALIFORNIA AUTHORITIES FOR TAX YEARS ENDING JUNE 30, 2009 AND BEFORE. 1 EAST ASIA AND THE PACIFIC - 0 0 PROGRAM SERVICES SPONSORED RESEARCH 60000 0 0 0 0 0 0 60000 0 60000 AUSTRALIA DIRECTED RESEARCH 60000 1 0 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCHER IS SUBECT TO TERMS AND CONDITIONS OF THE SPONSORED RESEARCH AGREEMENT BETWEEN THE UNIVERSITY AND THE MRF. THE RESEARCHER'S WORK IS REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND BY THE MRF RESEARCH AND DEVELOPMENT STAFF. 1 CASE WESTERN RESERVE UNIVERSITY 2109 ADELBERT ROAD CLEVELAND OH 44106 341018992 501(C)(3) 450000 MYELIN RESEARCH STANFORD UNIVERSITY FAIRCHILD BLDG RM D201A 200 CAMPUS DRIVE STANFORD CA 94305 941156365 501(C)(3) 300000 MYELIN RESEARCH UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE CHICAGO IL 60637 362177139 501(C)(3) 420000 MYELIN RESEARCH NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DR CHICAGO IL 60611 362167817 501(C)(3) 300000 MYELIN RESEARCH NATIONAL INSTITUTES OF HEALTH 31 CENTER DRIVE BETHESDA MD 20892 521986675 501(C)(3) 118750 MYELIN RESEARCH 5 0 PART I, LINE 2: THE UNIVERSITY IS SUBJECT TO TERMS AND CONDITIONS OF THE CONSORTIUM AGREEMENT BETWEEN THE UNIVERSITY AND THE MRF. THE RESEARCHER'S WORK IS REVIEWED BY THE SCIENTIFIC ADVISORY BOARD AND BY THE MRF RESEARCH AND DEVELOPMENT STAFF. X X X X 1 0 0 0 0 0 0 0 0 SCOTT JOHNSON CEO 264500 0 25000 0 0 0 0 0 39809 0 329309 0 0 0 JAY TUNG CRO 199654 0 15000 0 0 0 0 0 38889 0 253543 0 0 0 TASSIE COLLINS DIRECTOR 171910 0 16000 0 0 0 0 0 16252 0 204162 0 0 0 VIRGINIA SAIFER CDO 159973 0 0 0 9167 0 0 0 31287 0 200427 0 0 0 PART I, LINE 3 CEO AND CFO COMPENSATION IS DETERMINED BY THE INDEPENDENT COMPENSATION COMMITTEE. KEY EMPLOYEES' COMPENSATION IS DETERMINED BY AN ANNUAL REVIEW OF THE EMPLOYEE AND AN ANNUAL REVIEW OF THEIR COMPENSATION BY THE CEO AND CFO. THIS INFORMATION IS ALSO SHARED WITH THE INDEPENDENT COMPENSATION COMMITTEE. PART I, LINE 4A VIRGINIA SAIFER RECEIVED A SEVERANCE PACKAGE FOR $9,167 X 4 33213 FAIR MARKET VALUE X SMALL EQUIP 2 20623 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): THE NUMBER OF CONTRIBUTIONS REFLECTS THE NUMBER OF DONORS, NOT THE NUMBER OF ITEMS DONATED. SCHEDULE M, PART I, LINE 31: EXPLANATION: THE GIFT ACCEPTANCE POLICY INCLUDES THAT THE ORGANIZATION IS TO NOT ACCEPT ANY CONTRIBUTIONS OTHER THAN CASH OR PUBLICLY TRADED SECURITIES. FORM 990, PART VI, SECTION B, LINE 11 THE TAXPAYER'S ACCOUNTING FIRM FORWARDED THE FORM 990 TO THE CFO WHO THEN FORWARDED THE FORM 990 TO THE BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING THE FORM 990. BOARD MEMBERS WERE ENCOURAGED TO REVIEW THE FORM AND TO FORWARD THEIR QUESTIONS, IF ANY, TO THE CFO. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DRECTORS AND KEY EMPLOYEES ARE COVERED. ANY AND ALL CONFLICTS ARE REVIEWED BY DISINTERESTED BOARD MEMBERS AND, IF NEEDED, BY LEGAL COUNSEL. PERSONS WITH A CONFLICT OF INTEREST WILL BE RESTRICTED FROM MAKING KEY DECISIONS FOR MRF AS THEY RELATE TO THE INTEREST UNLESS OTHERWISE APPROVED BY THE MAJORITY OF THE DISINTERESTED BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE, WHICH IS COMPOSED OF THREE OF THE INDEPENDENT DIRECTORS, MUST REVIEW AND APPROVE ALL MANAGEMENT COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE. GOVERNING DOCUMENTS AND POLICIES ARE AVAILABLE UPON REQUEST.